Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT03793179 by National Cancer Institute (NCI), with a registry enrolment figure of 600 participants, started 2019-04-05 and due to reach its primary completion in 2027-09-30. Interventions recorded: Biospecimen Collection; Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Pembrolizumab; Pemetrexed; Positron Emission Tomography. Conditions listed: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "* Patients must have histologically or cytologically confirmed stage IV non-squamous non-small cell lung cancer (NSCLC) (includes M1a, M1b, and M1c stage disease, American Joint Committee on Cancer \[AJCC\] 8th edition)". Sites: Canada, Guam, United States. No results are recorded here; the registry entry is the source.